These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 33961991

  • 1. Antimicrobial susceptibility of bacteremic vancomycin-resistant Enterococcus faecium to eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics: Results from the 2019-2020 Nationwide Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART).
    Tsai HY, Lee YL, Liu PY, Lu MC, Shao PL, Lu PL, Cheng SH, Ko WC, Lin CY, Wu TS, Yen MY, Wang LS, Liu CP, Lee WS, Shi ZY, Chen YS, Wang FD, Tseng SH, Chen YH, Sheng WH, Lee CM, Chen YH, Liao CH, Hsueh PR.
    Int J Antimicrob Agents; 2021 Jul; 58(1):106353. PubMed ID: 33961991
    [Abstract] [Full Text] [Related]

  • 2. National surveillance of antimicrobial susceptibilities to dalbavancin, telavancin, tedizolid, eravacycline, omadacycline and other comparator antibiotics and serotype distribution of invasive Streptococcus pneumoniae isolates in adults: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) programme in 2017-2020.
    Chien YC, Lee YL, Liu PY, Lu MC, Shao PL, Lu PL, Cheng SH, Lin CY, Wu TS, Yen MY, Wang LS, Liu CP, Lee WS, Shi ZY, Chen YS, Wang FD, Tseng SH, Chen YH, Sheng WH, Lee CM, Chen YH, Ko WC, Hsueh PR.
    J Glob Antimicrob Resist; 2021 Sep; 26():308-316. PubMed ID: 34289409
    [Abstract] [Full Text] [Related]

  • 3. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).
    Lee DK, Kim Y, Park KS, Yang JW, Kim K, Ha NJ.
    J Biochem Mol Biol; 2007 Nov 30; 40(6):881-7. PubMed ID: 18047782
    [Abstract] [Full Text] [Related]

  • 4. Vancomycin-resistant Enterococcus faecium in Algeria: phenotypic and genotypic characterization of clinical isolates.
    Benamrouche N, Guettou B, Henniche FZ, Assaous F, Laouar H, Ziane H, Djennane F, Tiouit D, Bentchouala C, Yamouni F, Rahal K, Tali Maamar H.
    J Infect Dev Ctries; 2021 Jan 31; 15(1):95-101. PubMed ID: 33571151
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
    Belley A, Arhin FF, Moeck G.
    Antimicrob Agents Chemother; 2018 Jan 31; 62(1):. PubMed ID: 29109163
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
    Barber KE, Smith JR, Raut A, Rybak MJ.
    J Antimicrob Chemother; 2016 Jan 31; 71(1):152-5. PubMed ID: 26476277
    [Abstract] [Full Text] [Related]

  • 7. Utilizing genomic analyses to investigate the first outbreak of vanA vancomycin-resistant Enterococcus in Australia with emergence of daptomycin non-susceptibility.
    Douglas AP, Marshall C, Baines SL, Ritchie D, Szer J, Madigan V, Chan HT, Ballard SA, Howden BP, Buising K, Slavin MA.
    J Med Microbiol; 2019 Mar 31; 68(3):303-308. PubMed ID: 30663951
    [Abstract] [Full Text] [Related]

  • 8. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Jevitt LA, Smith AJ, Williams PP, Raney PM, McGowan JE, Tenover FC.
    Microb Drug Resist; 2003 Mar 31; 9(4):389-93. PubMed ID: 15000746
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Trends in susceptibility of vancomycin-resistant Enterococcus faecium to tigecycline, daptomycin, and linezolid and molecular epidemiology of the isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006 to 2010.
    Tsai HY, Liao CH, Chen YH, Lu PL, Huang CH, Lu CT, Chuang YC, Tsao SM, Chen YS, Liu YC, Chen WY, Jang TN, Lin HC, Chen CM, Shi ZY, Pan SC, Yang JL, Kung HC, Liu CE, Cheng YJ, Liu JW, Sun W, Wang LS, Ko WC, Yu KW, Chiang PC, Lee MH, Lee CM, Hsu GJ, Hsueh PR.
    Antimicrob Agents Chemother; 2012 Jun 31; 56(6):3402-5. PubMed ID: 22491684
    [Abstract] [Full Text] [Related]

  • 13. In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci.
    Arhin FF, Seguin DL, Belley A, Moeck G.
    Diagn Microbiol Infect Dis; 2017 Oct 31; 89(2):168-171. PubMed ID: 28733126
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antimicrobial susceptibility of enterococci recovered from healthy cattle, pigs and chickens in nine EU countries (EASSA Study) to critically important antibiotics.
    de Jong A, Simjee S, Garch FE, Moyaert H, Rose M, Youala M, Dry M, EASSA Study Group.
    Vet Microbiol; 2018 Mar 31; 216():168-175. PubMed ID: 29519512
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Daptomycin susceptibility testing and therapeutic use in enterococcal bloodstream infection (EBSI) in a setting with high rates of vancomycin-resistant Enterococcus faecium (VREfm).
    Kelly J, Tysall L, Dewar S.
    J Antimicrob Chemother; 2022 Apr 27; 77(5):1432-1435. PubMed ID: 35165738
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.